{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41"}],"title":"No pain or discomfort"},{"measurements":[{"groupId":"OG000","value":"55"}],"title":"Moderate pain or discomfort"},{"measurements":[{"groupId":"OG000","value":"9"}],"title":"Extreme pain or discomfort"},{"measurements":[{"groupId":"OG000","value":"3"}],"title":"Missing"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19"}],"title":"No pain or discomfort"},{"measurements":[{"groupId":"OG000","value":"38"}],"title":"Moderate pain or discomfort"},{"measurements":[{"groupId":"OG000","value":"5"}],"title":"Extreme pain or discomfort"},{"measurements":[{"groupId":"OG000","value":"46"}],"title":"Missing"}],"title":"Final Study Visit"}],"denoms":[{"counts":[{"groupId":"OG000","value":"108"}],"units":"Participants"}],"description":"Quality of Life (QoL) as measured by the European QoL 5-dimensional questionnaire (EQ-5D) for Cohorts A. The EQ-5D comprises asks for the current health state in the five dimensions: mobility, self care, usual activities, pain/discomfort, and anxiety/depression. Pain/discomfort scores assessed based on questionnaire. The categories of the response offer three levels pain/discomfort score: \"no pain or discomfort\" (score of 1), \"moderate pain or discomfort\" (score of 2), and \"extreme pain and discomfort\" (score of 3). Scores are presented from baseline to each visit for Cohort A.","groups":[{"description":"Subjects with Relapsed or Refractory CD30 positive Peripheral T-cell Lymphoma (PTCL).","id":"OG000","title":"Cohort A"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The full analysis set (FAS) followed the intent to treat (ITT) principle and consisted of all subjects who received at least one dose of AFM13.","reportingStatus":"POSTED","timeFrame":"At baseline and final study visit, up to 199 weeks.","title":"European Quality of Life 5-dimensional Pain/Discomfort Score (EQ-5D)","type":"SECONDARY","unitOfMeasure":"Participants"}